Objectives: * Learn about minoxidil clinical trials
* Learn about minoxidil efficacy
* Learn about novel oral adjuvant for minoxidil therapy
* Understand the results of the head-to-head study with the novel adjuvant
Introduction: Minoxidil has been used as a topical treatment for androgenetic alopecia (AGA) for more than 30 years. Unfortunately, clinical trials have demonstrated that approximately 60 to 70% of patients do not achieve hair growth following six months of treatment. Minoxidil is a pro-drug requiring conversion to minoxidil sulfate by sulfotransferase enzymes (SULT1A1). In this study, we report on a head-to-head study of the adjuvant therapy compared to minoxidil mono-therapy for AGA.
Materials / method: A novel oral formula was developed. 181 subjects recruited. Each subject was administered an oral supplement as an adjuvant for minoxidil b.i.d. Subjects TAHC was measured at baseline and week 12.
Results: 153 completed 12 weeks of the study. 70 women (average age 44.2) and 83 men (average age38.0).
Topical Minoxidil 5% + Botanical Sulfotransferase Supplement
At week 12, mean change in hair counts 21.8 (18.1)
At week 12, 35% (29/82) had experienced a significant hair growth*
Topical Minoxidil 5% + Multi-Vitamin Supplement
At week 12, mean change in hair counts 16.2 (16.7)
At week 12, 22.5% (16/71) had experienced a significant hair growth*
* Defined as more than 20% from baseline
Conclusion: The Topical Minoxidil 5% + Botanical Sulfotransferase Supplement was superior to the Topical
Minoxidil 5% + Multi-Vitamin Supplement for hair re-growth (approximately 35% more hair re-growth).
In addition, SULT1A1 enzymatic activity was significantly increased in the Botanical
Sulfotransferase Supplement group.
利益冲突声明
您有否接受任何资金来支持研究这个主题?
否
您是否接受过关于这项研究的任何酬金或其他报酬?
否
你是否和任何与您的研究所涉及的药物,材料或工具有密切联系的实体存在财务关系?
否
你是否拥有或者您已经为您此研究中的工具,药物或材料申请任何专利?
否
这项工作没有任何直接或间接的资金支持。由作者自己承担责任。